George R Simon MD
Executive Medical Director and Dept. Chair Moffitt-AdventHealth Joint Clinical Research Unit Professor of Medicine and Oncology H Lee Moffitt Cancer Center & USF Morsani School of Medicine
Join to View Full Profile
380 Celebration PlFl 2Celebration, FL 34747
Phone+1 843-792-1414
Fax+1 407-303-4803
Dr. Simon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 1992 - 1997
Saint Joseph HospitalResidency, Internal Medicine, 1993 - 1995
Christian Medical College LudhianaClass of 1986
Certifications & Licensure
FL State Medical License 2000 - 2026
OH State Medical License 2024 - 2026
OK State Medical License 2020 - 2021
TX State Medical License 2012 - 2021
SC State Medical License 2010 - 2013
PA State Medical License 2008 - 2010
CO State Medical License 1997 - 2009
American Board of Internal Medicine Medical Oncology- Join now to see all
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2009-2013
- Join now to see all
Clinical Trials
- Trial of Poor Performance Status Patients (ToPPS) Start of enrollment: 2009 Jun 01
- Cisplatin and Pemetrexed With Radiation Followed by Lobectomy Start of enrollment: 2011 May 01
- A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2012 Jan 01
Publications & Presentations
PubMed
- Social determinants of health and variability in treatment for patients with early-stage non-small cell lung cancer.Molly Scannell Bryan, Xiaohan Hu, Monika A Izano, Hina Mohammed, Marianna Wicks
JNCI Cancer Spectrum. 2025-03-03 - 2 citationsComplement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.Jeffrey M Clarke, George R Simon, Hirva Mamdani, Lin Gu, James E Herndon 2nd
Nature Communications. 2025-01-02 - Real-World and Clinical Trial Validation of a Deep Learning Radiomic Biomarker for PD-(L)1 Immune Checkpoint Inhibitor Response in Advanced Non-Small Cell Lung Cancer.Chiharu Sako, Chong Duan, Kevin Maresca, Sean Kent, Taly Gilat Schmidt
JCO Clinical Cancer Informatics. 2024-12-01
Press Mentions
Mesothelioma Treatment Program Expanding in Central FloridaSeptember 8th, 2021- Onc.AI Raises $6M Financing Round Co-Led by Blue Venture Fund and AccompliceDecember 3rd, 2020
- Delivering a Cancer-Free Frontier During COVID-19September 4th, 2020
- Join now to see all
Professional Memberships
- Member
- Fellow
Other Languages
- Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
